Company presentation

June 2020

NASDAQ: ASLN
TPEx: 6497

ASLAN PHARMACEUTICALS

Legal disclaimer

This presentation contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company's business strategy, the Company's plans to develop and commercialise its product candidates, the safety and efficacy of the Company's product candidates, the Company's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Company's product candidates. The Company's estimates, projections and other forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company's U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company's Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") on April 16, 2020.

All statements other than statements of historical fact are forward-looking statements. The words "believe," "may," "might," "could," "will," "aim," "estimate," "continue," "anticipate," "intend," "expect," "plan," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

Management team with global development experience

Position		Experience	
Dr Carl Firth CEO		AstraZeneca Head of New Portfolio (China) Head of BD (Asia)	Bank of America Merrill Lynch Head of Asia Healthcare Banking
Stephen Doyle CBO		Boehringer Ingelheim VP Specialty Care & Diabetes (China)	SANOFI VP Oncology (China)
Dr Bertil Lindmark Acting CMO		AstraZeneca Head of Development, R&I Head of Development, Japan	almirall feel the science Global Head of R&D CSO
Alison Ward VP R&D		AstraZeneca Respiratory & Inflammation	IPSEN Innovation for patient care Biologics process development
Kiran Asarpota VP Finance		GLOBAL BRANDS GROUP Group Finance Director	
Ben Goodger General Counsel		Osborne Clarke Senior Partner and Head of IP	EDWARDS WILDMAN Partner and Head of IP

Clinical-stage immunology & oncology biopharma developing innovative treatments to transform the lives of patients

Portfolio led by ASLAN004, a monoclonal antibody targeting IL-13Rα1, that has the potential to be best-in-disease for atopic dermatitis and asthma

Programs	Discovery	Preclinical	Phase 1	Phase 2	Anticipated milestones
Immunology					
ASLAN004 *IL-13Rα1 inhibitor*	Atopic dermatitis Asthma				• MAD interim data 2H 2020 • MAD completion 1H 2021
Oncology					
ASLAN003 *DHODH inhibitor*	AML				
Discovery					
AhR antagonist[1]	Oncology				

1 Aryl hydrocarbon receptor, or AhR, program is being developed in an ASLAN majority-owned joint venture

ASLAN004: the potential to lead a $21B market



- Atopic dermatitis (AD) is a large and growing market predicted to exceed $21 billion by 2027
- Biologics are changing the treatment paradigm in atopic dermatitis
- Dermatologists indicate the need for new, differentiated therapies

- ASLAN004 is a first-in-class inhibitor of the IL13 receptor and has the potential to be a best-in-disease therapy for AD
- Potential for improved efficacy, fewer adverse events and monthly dosing
- ASLAN004 is the only drug besides *dupilumab* to provide dual IL4/IL13 blockade, a validated approach which is becoming standard of care for moderate-to-severe AD
- Potential in asthma and other indications driven by allergic inflammation

- Phase 1 SAD in healthy volunteers complete. No significant adverse events noted to date. Profile may allow for monthly dosing
- Currently recruiting second cohort in MAD / PoC study. Early efficacy data encouraging. Expected completion in 1H 21
- Phase 2B to start in 2021

Atopic dermatitis is a chronic disease that can severely impact quality of life

Total AD prevalent cases

- Atopic dermatitis (AD) is a chronic inflammatory skin condition and the most common form of eczema
- Characterised by red inflamed skin and severe daytime and night-time itching
- Over 200 million AD patients worldwide
  - Prevalence estimated at 1-3% of adults worldwide
  - Up to 50% are moderate-to-severe patients

Market is being driven by biologics and systemic therapies

- There are few safe and effective treatments for moderate-to-severe AD
- Treatment traditionally focused on topical corticosteroids
- Systemic steroids associated with safety risks
- *Dupilumab* (approved in 2017) is the only biologic therapy available today
- *Dupilumab* has set a new standard for treating AD, but physicians are looking for better safety, improved efficacy, dosing regimen and convenience

Comparison of treatment options approved and in development for moderate-to-severe AD

	Efficacy	Safety	Dosing	Convenience	Possible use (if approved)
Target profile	+++	+++	+++	+++	
*Dupilumab (*IL4R)	++	++	+	+	Standard of care for systemic therapy
IL13 *eg lebrikizumab*	+	+++	+/++	?	When dupi can't be tolerated?
Pan-JAK eg *baricitinib*	+++	-	++	+++	
JAK-selective eg *abrocitinib*	+++	-/+	++	+++	When dupi fails?

AD is where the psoriasis market was 15 years ago

- The US psoriasis market grew from $1bn to $10bn in 15 years driven by the launch of biologics
- The AD landscape is poised for similar growth driven also by novel biologics
- AD market expected to exceed $21 billion by 2027



2025 market opportunity (US, EU and Japan)	Psoriasis[4]	AD[5]
Moderate-to-severe population (M)	3.3	13.6
Proportion treated with branded, systemic therapies (% of moderate-to-severe population)	16%	13%
Population treated with branded, systemic therapies (M)	0.5	1.8
Sales of branded, systemic therapies ($B)	**$12.9**	**$17.1**

Source: Decision Resources

Dupilumab has advanced the standard of care for AD, but a significant unmet need remains

- Launch of *dupilumab* in 2017 helped drive a large market for systemic AD therapy
- *Dupilumab* establishing dual blockade of IL4/IL13 biologic therapy as the new standard of care
- Sanofi intends to grow sales to over $11B
- However, there remains a significant unmet need
  - Only 35% of patients treated with *dupilumab* achieved an optimal response[1]
  - Conjunctivitis common and can lead to treatment discontinuations
  - Opportunity to improve on biweekly dosing regimen



1 Spherix (2018) Atopic dermatitis ATU study

Real world studies suggest conjunctivitis and eosinophilia may be more common and lead to treatment discontinuations

- In a review of 29 clinical studies, rates of conjunctivitis varied from 9 to 22%[1]
- Data from real world studies suggest rates in clinical practice may be much higher[2,3]
- Onset of conjunctivitis can be from weeks to months[1]
- In a recent retrospective study of 241 patients on *dupilumab:*
  - 38% of patients experienced conjunctivitis and 56% eosinophilia
  - 17% patients discontinued treatment mostly because of safety

Retrospective study of 241 AD patients taking *dupilumab*[2]

Adverse event	Patients (%)
At least 1 AE	171 (71)
Noninfectious ophthalmologic	107 (49)
Conjunctivitis	84 (38)
Ocular pruritus	52 (24)
Blepharitis	31 (14)
Xerophthalmia	27 (12)
Keratitis	14 (6)
Eosinophilia	100 (56)
Over 3x normal[4]	28 (30)

Reasons for discontinuation in 42 patients:



1 Agnihotri et al, 2019. *Drugs in R&*D. 19:311
2 Faiz et al, 2019. *JAAD.* 81:143. 241 moderate-to-severe AD pts collected in 2017 and 2018
3 Wollenberg et al, 2018. *J Allergy Clin Imm Pract*. 6:1778
4 Over 1500 cells/mm^3

ASLAN004 is a first-in-class IL-13R antibody that has the potential to be best-in-disease

Target profile:

A drug that can deliver better efficacy over current standard of care

A drug that allows monthly dosing for patients improving convenience and compliance

A drug that addresses physician concerns on safety with lower rate of discontinuation

A drug with greater storage flexibility allowing it to be stored at room temperature

ASLAN004 is the only drug besides *dupilumab* to provide dual IL4 / IL13 blockade



ASLAN004 blocks the formation of the Type II receptor, preventing signalling through both IL4 and IL13

Dual-blockade (receptor targeting) appears clinically to be more effective

IL4/IL13 receptor targeting		
ASLAN004 (ASLAN)	IL13Rα1	Phase 1 / POC in atopic dermatitis
Dupilumab (Sanofi / Regeneron)	IL4Rα	Approved in atopic dermatitis and allergic asthma

IL4/IL13 ligand targeting		
Lebrikizumab (Eli Lilly / Dermira)	IL13	Discontinued in asthma, phase 3 in atopic dermatitis
Tralokinumab (Leo)	IL13	Discontinued in asthma, phase 3 in atopic dermatitis
Altrakincept (Amgen)	IL4	Discontinued
Pascolizumab (GSK)	IL4	Discontinued



Dupilumab-associated conjunctivitis may be driven by inhibition of Type I receptor, which ASLAN004 does not bind



- *Dupilumab* blocks the Type I receptor
- This may drive T_H2 to T_H1 polarisation
- T_H1 cells product interferon gamma, which can lead to apoptosis of goblet cells
- This could lower the production of mucin and lead to development of dry eye and conjunctivitis

Source: Guttman-Yassky et al 2020. *JAMA Derm* 156:411

ASLAN004 binds more strongly to receptor than *dupilumab* relative to its respective ligand

Receptor	Ligand	K_D (nM)	Comments
IL-13Rα1	IL-13	30[1]	ASLAN004 has a 60 fold higher affinity for receptor than IL-13
IL-13Rα1	ASLAN004	0.5	
IL-4Rα	IL-4	0.1[1]	*Dupilumab* only has a 3 fold higher affinity for receptor than IL-4
IL-4Rα	*Dupilumab*	0.03	





Need to repeat dose to avoid concentration falling

ASLAN004 offers a greater affinity difference between ligand and receptor binding which may translate to lower required concentration *in vivo* and may provide improved dosing frequency and efficacy

1 Kraich et al (2006) BMC Biology 4:13

Phase 1 SAD study in healthy volunteers completed

- Well tolerated at all doses when administered IV and subcutaneous (SC)
  - No adverse events that led to discontinuations, no significant injection site reactions
  - SC now used in on-going studies
- Analysis of downstream mediators including pSTAT6 demonstrated complete inhibition within one hour of dosing with IV and maintained for more than 29 days
- PK profile may allow for monthly dosing
- Concentration required to completely inhibit signal transduction via the receptor was over an order of magnitude lower than that of existing therapies



ASLAN004 well-tolerated at all dose levels

Drug-related adverse event	N = 44				
	Any grade		Severity		
	N	(%)	Mild	Moderate	Severe
Decreased appetite	2	5	1	1	0
Alanine aminotransferase increased	1	2	1	0	0
Diarrhoea	1	2	1	0	0
Pyrexia	1	2	1	0	0
Blood lactate dehydrogenase increase	1	2	1	0	0
Weight decrease	1	2	1	0	0
Lymphocyte count decrease	1	2	1	0	0
Headache	1	2	0	1	0
C-reactive protein increase	1	2	1	0	0
Injection site pruritus (mild)	1	2	1	0	0

ASLAN004 MAD is designed to deliver PoC

- MAD / PoC study testing ASLAN004 in moderate-severe AD patients
- Double-blind, placebo-controlled study
- Patients dosed for 8 weeks with a 12-week recovery period
- Patients recruited from Singapore, opening sites in Australia and US
- Interim unblinded data from cohorts 1-3 expected 2H 20, with completion in 1H 21



Primary endpoints are safety and tolerability

Secondary endpoints include percentage change in EASI score (EASI50, EASI75) pruritus score and IGA, TARC, IgE

Study has 80% power to detect a 39% improvement in the percentage change in EASI score from baseline based on a one-sided 5% significance level

Early signs of efficacy in low dose cohort

- First patient enrolled on 22 October 2019
- As of 29 November 2019, 6 patients treated in low dose (200mg) cohort
- Currently recruiting 2nd dose cohort
- ASLAN004 well-tolerated, with no serious AEs or treatment discontinuation
- 3 patients completed at least 1 month of dosing with average reduction in EASI of 71%
- Maximal efficacy expected at 6 to 8 weeks



ASLAN004 has the potential to be best-in-disease

IL-13Rα1 inhibitor	ASLAN004 is the only monoclonal antibody targeting IL-13Rα1, and has the potential to be best-in-disease for atopic dermatitis and asthma
Validated pathway	Targets the same pathway and receptor complex (Type II) as *dupilumab*
Targeting differentiated profile	Potential for improved efficacy, fewer adverse events, monthly dosing
SAD completed	Phase 1 SAD in healthy volunteers completed. No significant adverse events noted to date. Profile may allow for monthly dosing.
MAD/PoC ongoing	Currently recruiting second cohort in MAD / PoC study. Early efficacy data encouraging. Expecting interim data 2H 20, completion in 1H 21
Phase 2b program	Planning to initiate phase 2b program in 2021
Potential in other indications	Potential to pursue development in other indications where *dupilumab* has proven to be effective

Financials

Financials

Shares outstanding	Overall	NASDAQ: ASLN	TPEx: 6497 (Taiwan)
Ordinary shares	190M	59M	130M
ADS equivalent (5:1)	38M	12M	26M
Net loss	US$ 3.0M (1Q 20)		
Cash balance	US$ 16.9M (1Q 20)		
Recent financing	US$ 14.7M raised in Dec 2019 (NASDAQ follow-on)		